États-Unis · Bourse & Finance · MarketWatch

Zealand Pharma Shares Drop After Boehringer Obesity Drug Trial Results

Publié par MarketWatch · États-Unis il y a 10 h

Zealand Pharma shares fell after German partner Boehringer Ingelheim reported results from a late-stage clinical trial of an obesity drug candidate licensed from the Danish…

Lire l'article complet sur MarketWatch Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketwatch.com)

Zealand Pharma Shares Drop After Boehringer Obesity Drug Trial Results

À lire aussi

McGraw Hill cuts another $50M of debt, targets 2-2.5x leverage

Senate Democrats are questioning the legality of the Pentagon's Venezuela oil deal

Indian Refiners Seek Tankers for Hormuz Oil

Morning Minute: Crypto Gives Up on Congress and Goes After Senators

New York Times Reporting Through a Front Page That Never Published and More

Satlyt, founded by a former Google and SpaceX product manager, raises $8M to run AI on satellites

Zealand Pharma Shares Drop After Boehringer Obesity Drug Trial Results

Partager

À lire aussi

McGraw Hill cuts another $50M of debt, targets 2-2.5x leverage

Senate Democrats are questioning the legality of the Pentagon's Venezuela oil deal

Indian Refiners Seek Tankers for Hormuz Oil

Morning Minute: Crypto Gives Up on Congress and Goes After Senators

New York Times Reporting Through a Front Page That Never Published and More

Satlyt, founded by a former Google and SpaceX product manager, raises $8M to run AI on satellites